A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Sevacizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; First in man
- Sponsors Jiangsu T-mab BioPharma
- 27 Feb 2018 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 27 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2018.
- 15 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.